Yahoo Finance Live's Brad Smith discusses how BioNTech stock is trading amid earnings.
BRAD SMITH: Before we head to break let's look at shares of BioNTech, ticker symbol BNTX. It's missed earnings on both the top and bottom lines. BioNTech, the company which partnered with Pfizer, to help develop the first COVID-19 vaccine approved for use in the United States, did say that they expect an uptick in demand during the fourth quarter of 2022, subject to regulatory approval. That includes approval on their Omicron-adapted vaccines, which should be ready for delivery as early as October.